Exelixis sales and marketing update

Exelixis launched Cometriq cabozantinib in the U.S. to treat progressive, metastatic medullary thyroid cancer (MTC). The wholesale acquisition cost is $9,900 for a 28-day supply. The spectrum-selecti...